Skip to main content

Drug to Limit Stroke Damage Shows Promise in Human Trials

By Sponsored

A new drug called NA-1 developed in Canada is showing a lot of promised in a limited study conducted in Toronto. While the study is a fledgling at phase 2 trials there is a lot of promising proof that offers hope for future stroke victims. The side effects noted in this study were almost non-existent with only two patients suffering major strokes during an operation. These incidents are believed to be related to an underlying condition and not the treatment itself.

The major setback when it comes to stroke treatment is that the time frame for treatment is very limited. The current treatment requires that the clot busting drugs be given within the first four and a half hours in order to prevent damage. The time it takes to diagnose the cause of the stroke and getting the patient treatment this timeline is often exceeded.

Researchers responsible for the new drug are working in a field that has been virtually abandoned by pharmaceuticals due to repeated failures. The researchers started a company named NoNO Inc, an ironic name standing for no nitric oxide which is responsible for causing damage to sensitive brain tissues during a stroke.

The trial was a limited but focused study of 185 patients but the results showed real promise according to the data. The test subjects who received NA-1 had approximately fifty percent less strokes than the patients who were given the placebo. An additional benefit of NA-1 was discovered on patients who needed surgery to repair damage as there was much less damage found than was expected.

Source: Ottawa Citizen

Sponsored

Contributor

Angela is the editor of Activebeat and is an avid health enthusiast. She’s our source for great fitness and exercise tips and is dedicated to bringing you the breaking news stories each day. From recalls and outbreaks to FDA announcements and alerts, she’ll keep you up-to-date with the most important health news every day.

Health Studies in the News

Explore

What is Eye Movement Desensitization and Reprocessing (EMDR) Therapy?
By Katherine George Your Health

What is Eye Movement Desensitization and Reprocessing (EMDR) Therapy?

EMDR is a fairly new and nontradiational type of psychotherapy. It has become increasingly popular for treating PTSD. To learn more about it, here’s a look into what it is, how it works, if it’s effective, and the potential risks and benefits…

Read More about What is Eye Movement Desensitization and Reprocessing (EMDR) Therapy?

7 min read

Lung Cancer Rates Have Decreased for the Marlboro Man, but Have Risen Steeply for Nonsmokers and Young Women – An Oncologist Explains Why
By Estelamari Rodriguez Your Health

Lung Cancer Rates Have Decreased for the Marlboro Man, but Have Risen Steeply for Nonsmokers and Young Women – An Oncologist Explains Why

When many people think of an average lung cancer patient, they often imagine an older man smoking. But the face of lung cancer has changed. Over the past 15 years, more women, never smokers and younger people are being diagnosed with lung cancer. In fact, lung cancer is the leading cause of cancer death among […]

Read More about Lung Cancer Rates Have Decreased for the Marlboro Man, but Have Risen Steeply for Nonsmokers and Young Women – An Oncologist Explains Why

4 min read

Ultra-Processed Foods – Like Cookies, Chips, Frozen Meals and Fast Food – May Contribute to Cognitive Decline
By Sara N. Burke Your Health

Ultra-Processed Foods – Like Cookies, Chips, Frozen Meals and Fast Food – May Contribute to Cognitive Decline

Scientists have known for years that unhealthy diets – particularly those that are high in fat and sugar – may cause detrimental changes to the brain and lead to cognitive impairment. Many factors that contribute to cognitive decline are out of a person’s control, such as genetics and socioeconomic factors. But ongoing research increasingly indicates […]

Read More about Ultra-Processed Foods – Like Cookies, Chips, Frozen Meals and Fast Food – May Contribute to Cognitive Decline

5 min read